FT. LAUDERDALE, FL--(Marketwire - May 26, 2010) - Macada Holding, Inc. (PINKSHEETS: MCDA) announced that its subsidiary Lyfetec, Inc. has signed a purchase agreement which will help minimize or help prevent staph infections and most infectious bacteria. Revolutionary advancements in this patented formula design have yielded overwhelming results from the University of Switzerland. The integration into our new product line will soon to be announced and will drastically saves the lives of people across the globe, who will otherwise die by the contraction of Staph infections while receiving hospitals treatments. This is a full scale production and distribution not a research and development operation.
Chief Scientist Byron Ziegler states, “It is a great day at MCDA. The integration of the formula can stand alone or be infused into other products such as Surgical equipment, paints, detergents, air filtration systems and many other anti-bacteria products.”
The figures from England’s last report being 320,000 infections, Professor Gastmeier estimates 14,000 cases per year of MRSA in Germany and at 1.7 million cases per year in the United States, a large increase in patients with the MRSA infections.
“Nosocomial infections have considerable significance for the hospitals in Germany,” says Professor Gastmeier. “They extend the length of time spent in hospitals, more expensive therapy and endanger the lives of many people. Preventive measures have therefore remained a high priority. PhytoBionic offers its customers not only production technology and environmental benefits through the patented coating technology. Complete coating systems and solutions are PhytoBionic customized developed and delivered in series and reduce complexity and for the customer costs by optimized results.”
Inventor Christan Maas, a bio-chemist, created this Bacteria coating which protects and sterilizes. Nosocomial infections are identified as a problem jeopardizing the life of many patients. Endowment of implantable biomaterials with antimicrobial activity as well as a genuine germfree environment is mandatory as bacterial microorganisms show substantially increasing rates of resistance.
Anthony Mellone stated: “The direct beneficiaries of this germ fighting agent solution product are patients of hospitals, health care facilities, labs and other medical facilities and consumers for personal use in their homes. This application kills 98.9% of the bacteria and staff germs on surfaces and is expected to be available to the public within the next 60 days.”
Safe Harbor Provision
This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Macada Holding, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, the availability of technical personnel, changes in technology and competition.
Contact:
Ron Ritter
954-782-2056
